Menu Back toComplimentary: Regulatory and Real World Evidence Challenges of Rare Diseases and Orphan Drugs

Complimentary: Regulatory and Real World Evidence Challenges of Rare Diseases and Orphan Drugs


This Solution Provider Webinar is brought to you by DIA in cooperation with Optum.

Therapeutics for rare diseases face unique challenges in addressing regulatory and market access requirements around the world.  This webinar will provide an overview of the European, US and Canadian landscapes for these products. Our speakers will share their experience from the regulatory, market access and commercial perspectives. 

This webinar is available for order until May 31, 2015
Duration:  1 hour 28 minutes


Featured topics

  • The Regulatory perspective: Patricia Anderson, Optum
  • The Market access perspective: Karl Gregor, Optum
  • The Commercial perspective: Mike Cloutier, InterMune Canada Inc.

Who should attend?

Professionals who work in the area of:

  • Regulatory affairs
  • Marketing and commercialization
  • Market access and pricing
  • Health policy and reimbursement
  • Health economics and outcomes research

Learning objectives

At the conclusion of this webinar, participants should be able to:

  • Describe the current challenges facing life sciences companies with orphan drugs in development
  • Compare regional differences in requirements for achieving orphan drug designation, approval and reimbursement
  • Contrast value assessment considerations by HTA bodies and payers
  • Identify solutions to address the unique regulatory, payer and commercial challenges for orphan drugs

Contact us

Registration Questions
Toll Free 1.888.257.6457
Phone +1.215.442.6100
Fax +1.215.442.6199
Monday-Friday 8:30AM-8:00PM ET

Archived Webinar Details
Jessica Culp
DIA North America
Phone +1.215.442.6132
Fax +1.215.442.6199